|
燕思佳.血管免疫母细胞T细胞淋巴瘤的治疗进展[J].内科急危重症杂志,2026,32(2):192-198
|
| DOI：10.11768/nkjwzzzz20260218 |
| 中文关键词: 血管免疫母细胞T细胞淋巴瘤 CHOP 复发难治 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 121 |
| 全文下载次数: 146 |
| 中文摘要: |
| 摘要 血管免疫母细胞T细胞淋巴瘤是一种常见的外周T细胞淋巴瘤。目前对于其治疗，初治患者常采用环磷酰胺联合多柔比星、长春新碱与泼尼松（CHOP）或CHOP样方案进行化疗，同时多种新型作用机制的药物正在开展临床试验。但是复发后患者预后差，尚无用于其治疗的标准方案，多项临床试验正在进行。 |
| 英文摘要: |
| Abstract Angioimmunoblastic T-cell lymphoma (AITL) is a common type of peripheral T cell lymphoma. Currently, CHOP (Cyclophosphamide + Doxorubicin + Vincritine + Prenidone)/ CHOP-like regimens are commonly used for chemotherapy in newly treated patients, and several drugs with novel mechanisms are undergoing clinical trials. However, the prognosis of patients with relapse is poor, and there is no standard regimen for its treatment. Multiple clinical trials are in progress. |
|
